This story first appeared in The Readout newsletter. Sign up for The Readout and receive STAT’s award-winning biotech news delivered straight to your inbox.
Hello! Today, we talk about how much dang money some CEOs still make, despite the slowdown in the biotech industry. We also see Dupixent approved for a huge new indication, and more.
Click this link for the original source of this article.
Author: Meghana Keshavan
This content is courtesy of, and owned and copyrighted by, https://www.statnews.com and its author. This content is made available by use of the public RSS feed offered by the host site and is used for educational purposes only. If you are the author or represent the host site and would like this content removed now and in the future, please contact USSANews.com using the email address in the Contact page found in the website menu.
